RAYNHAM, Mass., May 11, 2011 /PRNewswire/ — Doctors in Germany
are among the first to treat ischemic stroke patients outside the
United States with the REVIVE™ SE, a new self-expanding blood
clot retrieval and removal device designed to remove blood clots
and restore blood flow to the brain in patients having a stroke.
Codman & Shurtleff, Inc., a global neuroscience and
neurovascular company, received Conformite Europeenne (CE) mark
authorization for the REVIVE™ SE in February 2011. CE mark
approval means that the product has been deemed safe for use in
occlusions or blockages in blood vessels or grafts and can now be
marketed for this indication in all Member States of the European
Union (EU), European Economic Area and Switzerland. The device is
not approved for distribution in the United States.
“This device is an important new option because it may provide
advantages over currently available treatments,” said Martin
Bendszus*, MD, Department of Neuroradiology, University of
Heidelberg in Germany, who has successfully treated more than 25
patients with the REVIVE™ SE. “Patients treated with
neurothrombectomy devices such as REVIVE™ SE may achieve
rapid recanalization, enhanced efficacy in treating larger vessel
occlusions and thus have an improved clinical outcome.”
The REVIVE™ SE provides physicians with a new option for
treating ischemic stroke, which occurs when not enough blood gets
to the brain and causes symptoms including sudden numbness or
weakness of the face, arms or legs, confusion, vision loss,
dizziness or severe headache. The device is a self-expanding
nitinol basket that provides a temporary bypass across the
occlusion in the brain. It can also be used for the non-surgical
removal of emboli and thrombi, and be used with aspiration.
“Every stroke is different, and we are now exploring the use of
imaging to determine which patients may benefit most from treatment
with RE
‘/>”/>
